In line with these findings, Wium-Andersen et al. reported that low doses of metformin, DPP4 inhibitors, GLP1 agonists, and SGLT2 inhibitors were associated with a reduced risk of depressive disorder in patients with diabetes compared with non-users, with the greatest risk reduction observed for SGLT2 inhibitors (OR 0.55, 95% CI: 0.44–0.70). The gene discussed is SLC5A2; the disease is diabetes mellitus.